Ecuphar Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 21

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 4

  • Investments
  • 3

Ecuphar General Information

Description

Developer, marketer and distributor of veterinary pharmaceuticals. The company's veterinary pharmaceuticals include OTC and registered products for pets such as dogs, cats, horses, birds as well as for farm animals, enabling the customers to get access to all the pharmaceutical products for their pets in need.

Contact Information

Website
www.ecuphar.com
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Corporate Office
  • Legeweg 157/D
  • 8020 Oostkamp
  • Belgium
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Pharmaceuticals
Acquirer
Corporate Office
  • Legeweg 157/D
  • 8020 Oostkamp
  • Belgium

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ecuphar Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Ecuphar‘s full profile, request access.

Request a free trial

Ecuphar Patents

Ecuphar Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-12208085-B2 Pyrazoline-derived compound for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals Active 31-May-2022
US-20230381140-A1 Pyrazoline-derived compound for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals Active 31-May-2022
EP-4029502-A1 Pyrazoline-derived compound (enflicoxib) for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals Pending 15-Jan-2021
ES-2828435-T3 Compound derived from pyrazoline and its use in a weekly regimen against inflammation and pain derived from degenerative joint disease in mammals Active 16-Oct-2014
JP-6655625-B2 Pyrazolin-derived compounds and their use in weekly dosing regimens for inflammation and pain from osteoarthritis in mammals Active 16-Oct-2014 A61K31/415
To view Ecuphar’s complete patent history, request access »

Ecuphar Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ecuphar Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Ecuphar‘s full profile, request access.

Request a free trial

Ecuphar Investments (3)

Ecuphar’s most recent deal was a Buyout/LBO with Esteve (Veterinary Division). The deal was made on 05-May-2015.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Esteve (Veterinary Division) 05-May-2015 Buyout/LBO Other Commercial Products
Riemser Arzneimittel (Veterinary Business) 29-Jun-2011 Buyout/LBO Drug Delivery
NutriScience 01-Jan-2009 Buyout/LBO Other Consumer Non-Durables
To view Ecuphar’s complete investments history, request access »

Ecuphar Exits (1)

Ecuphar’s most recent exit was on 01-Jan-2009 from NutriScience. The exit was categorized as with 4 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
NutriScience 01-Jan-2009 Completed
  • 4 buyers
To view Ecuphar’s complete exits history, request access »

Ecuphar Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Ecuphar Veterinary Products Breda, Netherlands 2001
Euracon Pharma Consulting & Trading Greifswald, Germany 1995

Ecuphar FAQs

  • When was Ecuphar founded?

    Ecuphar was founded in 2003.

  • Where is Ecuphar headquartered?

    Ecuphar is headquartered in Oostkamp, Belgium.

  • What is the size of Ecuphar?

    Ecuphar has 21 total employees.

  • What industry is Ecuphar in?

    Ecuphar’s primary industry is Drug Delivery.

  • Is Ecuphar a private or public company?

    Ecuphar is a Private company.

  • What is the current valuation of Ecuphar?

    The current valuation of Ecuphar is .

  • What is Ecuphar’s current revenue?

    The current revenue for Ecuphar is .

  • How much funding has Ecuphar raised over time?

    Ecuphar has raised $14.5M.

  • Who are Ecuphar’s investors?

    CARDON Pharmaceuticals, Capital@rent, Omega Pharma (Nazareth), Partners at Venture, and Pentahold have invested in Ecuphar.

  • When was Ecuphar acquired?

    Ecuphar was acquired on 13-Jul-2017.

  • Who acquired Ecuphar?

    Ecuphar was acquired by Animalcare Group.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process